Analysts offer poor odds of success for most advanced Alzheimer's drugs; Bankrupt Northfield settles PolyHeme fraud claim;

@FierceBiotech: Eli Lilly aims to up game Item | Follow @FierceBiotech

@JohnCFierce: In latest R&D setback, Lilly's schizophrenia drug flunks a PhIII (and yes, it is a big deal) More | Follow @JohnCFierce

@RyanMFierce: Interesting to see ‪genomics‬ firm 23andMe build ‪social web‬ presence with CureTogether buyout. More | Follow @RyanMFierce

> Bloomberg takes another turn sizing up the rather poor odds being assigned to the two late-stage Alzheimer's drugs in the clinic. Eli Lilly and rivals at J&J/Pfizer will announce Phase III data later this year. Story

> Three years after going out of business, Northfield Laboratories has settled a securities fraud suit brought over its claims for the blood substitute PolyHeme. Story

> Canada's Cangene has cancelled its product development program for Immune Globulin Intravenous, an anti-infective used for a variety of indications. Release

Pharma News

 @FiercePharma: Judge chastises for silence on AstraZeneca petition against generic Seroquel. Forced us into 'fire drill,' he says Item | Follow @FiercePharma

> Don't look for Arena's Belviq to take Japan by storm, analysts say. Story

> Glaxo's new HIV combo trounces Gilead's Atripla. News

> New cancer drugs debut faster in U.S., but they cost more. Item

> Lilly aims to harmonize its social-media voices. Article

Medical Device News

@FierceMedDev: Mako's declining sales estimates for its surgical robot devices caused investors to drive the stock down 43%. Ouch. More | Follow @FierceMedDev

@MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

@DamianFierce: As Obama signs the FDA reauthorization bill, device groups remain optimistic for a more efficient future. More | Follow @DamianFierce

> Neuravi reels in $6.5M Series A for stroke treatment device. Article

> Terumo completes enrollment in stent study for FDA, Japanese regulators. Story

> Drug-eluting stents deployed too much, researchers conclude. News

> Bloomberg: 3i Group looking to unload Dx firm Labco. Item

Biomarkers News

> Counting eosinophils signpost survival in coronary artery disease. Item

> Colorectal cancer marker tags poor outcomes. Article

> Pronota biomarker test recognizes preeclampsia. Story

> Immune cells counted to predict survival after angioplasty. News

Drug Delivery News

> SRI gets Defense grant to develop oral-delivered MS drug. News

> QLT seeks options for eye drug delivery tech in major shakeup. Article

> Harvard docs use nanoparticles to get drugs to clotted arteries. Story

> Biotech builds IPO case on cancer drug delivery platform. Item

And Finally... Turns out that the bigger the small region of your brain is, the more likely it is you'll be altruistic. Release

 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.